A New ‘Living Medicine’ for Osteoporosis Cut Fractures by 94 Percent

A tiny trial hints at turning patients’ own cells into targeted living medicine.

A minor fall can be enough to break a bone in someone with advanced osteoporosis. The disease slowly erodes the skeleton from within, leaving bones increasingly fragile as the body loses them faster than it can rebuild them.

That makes osteoporosis an appealing target for regenerative medicine. Bone-building cells already exist in the body, but doctors would need to deliver them throughout the skeleton to treat osteoporosis effectively.

Researchers may now have an answer to that problem.

In a first-in-human Phase 1 trial, scientists took bone-marrow cells from 10 women with severe osteoporosis, modified their surfaces, and infused them back into the bloodstream. The modification acted like a temporary molecular address label, intended to help the cells find their way back to bone.

The study was designed mainly to test safety. But researchers also observed that fractures fell sharply after treatment, while biopsies and specialized scans suggested improvement in the spongy inner structure of bone.

The trial is far too small to prove that the therapy works. At least, for now. But the underlying idea reaches beyond osteoporosis. If scientists can reliably tell therapeutic cells where to go, they may be able to turn them into targeted “living medicines” for damaged tissues elsewhere in the body.

Giving cells a ZIP code

The cells, called mesenchymal stromal cells (MSC), live in bone marrow and can give rise to osteoblasts—bone building cells. The catch is that when MSCs are grown in a laboratory and injected into a vein, they are poor navigators.

The researchers changed that by tinkering with the glycocalyx, the sugary coating on the outside of a cell. They added a sugar called fucose to a molecule called CD44, completing a surface structure known as sialyl Lewis X. That structure can latch onto E-selectin, a molecule lining specialized blood vessels in bone marrow.

×

Get smarter every day...

Stay ahead with ZME Science and subscribe.

Daily Newsletter
The science you need to know, every weekday.

Weekly Newsletter
A week in science, all in one place. Sends every Sunday.
No spam, ever. Unsubscribe anytime. Review our Privacy Policy.

Thank you! One more thing...

Please check your inbox and confirm your subscription.

In other words, the team temporarily stuck a destination tag on the cells. The tag lasts roughly 48 hours—apparently long enough to help circulating cells slow down along marrow blood vessels and enter the tissue.

The approach traces back to a 2008 Nature Medicine study in mice, in which Robert Sackstein and colleagues showed that the same glycan engineering could steer human MSCs into bone marrow.

For the new study, researchers drew about 60 milliliters of marrow from each woman’s hip, expanded the MSCs in culture, modified their surfaces and delivered a single intravenous dose. The women were 51 to 72 years old and had already suffered osteoporosis-related fractures.

With Great Signals Come Important Caveats

Over the first two years after infusion, fragility fractures across the group fell from 8 per year to 0.5 per year—a stunning 94% reduction. Average bone tissue area in biopsies increased four months after treatment, and a CT-based measure of trabecular, or spongy, bone quality improved by two years. Conventional DXA bone-density measurements, however, did not show significant group-level improvements.

The researchers followed the participants for a median of about six years and reported no serious adverse events attributable to the cell infusion.

“It’s quite remarkable,” Ajit Varki, a physician-scientist at the University of California, San Diego, who was not involved in the research, told Nature. “[The trial] showed an almost 100% efficacy sustained for several years—and no side effects.”

But 10 patients are nowhere near enough to establish that the therapy prevents fractures. Without a randomized control group, the researchers could not tell how much the engineered cells contributed to the drop in fractures. Most participants also received conventional osteoporosis treatments, and some changed medications during follow-up, further complicating the picture. Nor could the researchers directly track the infused cells inside people to prove where they went. A larger randomized trial will be needed to tease apart those effects.

RelatedPosts

Scientists Regrow Amputated Toes in Mice. Could the Same Process Work in Humans?
Scientists Turn On Hidden Genetic Switch That Could One Day Help Humans Regrow Lost Limbs
Researchers successfully regrow limbs on frogs. They want to do the same thing with humans
Finally, mRNA vaccines against cancer are starting to become a reality

Robert Sackstein, one of the study authors and a developer of the glycocalyx-engineering approach, holds intellectual-property rights related to the technology under NIH policies. That does not invalidate the findings, but it is important context as the technique moves toward larger clinical trials and possible commercialization.

Still, the experiment tests something larger than another osteoporosis treatment. More than 15 years after researchers first demonstrated the approach in mice, the new trial offers early evidence that scientists can steer therapeutic cells to a chosen tissue without permanently changing their DNA.

If that principle holds up, osteoporosis may be only one stop on the map.

The study was published in the journal Cell.